Recent News
On September 23, 2025 Monopar announced pricing of an underwritten offering expected to generate approximately $100.0 million in gross proceeds from sales of common stock and pre‑funded warrants. On October 13, 2025 Barclays initiated coverage of Monopar with an Overweight recommendation and updated one‑year price forecasts. On October 15–16, 2025 Monopar disclosed that an abstract for its Phase 2 ALXN1840 copper balance study received oral presentation acceptance at AASLD – The Liver Meeting® 2025 (presentation scheduled November 9, 2025).
Technical Analysis
ADX at 11.75 signals no strong trend; the low ADX suggests price action lacks directional conviction despite fresh news and valuation context.
DI+ measures 18.5 and trends decreasing while DI− stands at 22.04 and trends increasing; those directional indicators point to a bearish bias in the near term, placing downward pressure on price momentum relative to the longer-term valuation case.
MACD at −2.35 sits below its signal line (signal −1.03) and trends decreasing, indicating bearish momentum and reinforcing short-term downside bias rather than a bullish crossover that would signal improving momentum.
MRO registers −0.62 with a dip & reversal trend; the negative MRO indicates price sits below the quantitative target and therefore contains potential upside pressure toward fair value, which complements the company’s valuation profile despite short-term bearish momentum.
RSI at 48.92 and decreasing reflects weakening momentum around a neutral level, consistent with short-term consolidation beneath shorter moving averages.
Price sits at $67.70, below the 12‑day EMA ($75.72, decreasing) and below the 20‑ and 50‑day averages ($77.02 and $82.77), indicating short-term weakness. Price remains above the 200‑day average ($51.96), preserving longer‑term positive context that aligns with the under‑valued determination.
Bollinger bands show the 1x lower band at $71.91 and the 2x lower band at $66.81; current price below the 1x lower band but above the 2x lower band suggests near‑term mean‑reversion potential without an extreme oversold condition. Ichimoku lines place Senkou A at $84.72 and Senkou B at $67.09, with price near Senkou B—this situates the stock close to a cloud boundary that often marks short‑term support/resistance tension.
Fundamental Analysis
Cash and short‑term investments total $143,675,787 and operating cash flows for the period show an outflow of $2,452,665; free cash flow stands at −$2,090,532. The company maintains large liquid resources that underwrite ongoing clinical programs and the regulatory timeline tied to ALXN1840 and radiopharmaceutical clinical efforts.
EPS actual registered at −$0.48 versus an estimate of −$0.40, a miss of $0.08 representing a −20% EPS surprise. Net income from continuing operations totaled −$3,437,601; EBIT and EBITDA both at −$4,093,075 reflect ongoing development spending, with research and development expense of $2,589,749 supporting clinical progress.
Return on assets equals −3.47% and return on equity equals −2.43%, both negative and reflecting a clinical‑stage company profile; earnings growth figures show mixed short‑term movements (earnings growth QoQ −570.46% and YoY −242.86% as reported), driven by timing of program spending and financing.
Liquidity ratios remain exceptionally strong: current ratio at 56.10 and cash ratio at 55.94, supported by a modest total debt level ($70,881) and debt to assets of 0.049%. The capital structure provides runway for planned NDA assembly and radiopharmaceutical trial activity through the stated period.
Price‑to‑book sits at 3.37, below the industry peer mean of 6.97 and the industry peer median of 5.80 while above the peer low of −8.56; PEG ratio at −4.01 lies above the industry peer low (−4.86) but below the peer mean (0.06). Negative P/E and forward P/E metrics reflect loss‑making status and expected negative near‑term earnings. WMDST values the stock as under‑valued, with the balance sheet supporting continued program execution while fundamentals remain typical for a clinical‑stage biotech.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-09-30 |
| REPORT DATE: | 2025-11-13 |
| NEXT REPORT DATE: | 2026-02-12 |
| CASH FLOW | Begin Period Cash Flow | $ 39.5 M |
| Operating Cash Flow | $ -2.45 M | |
| Capital Expenditures | — | |
| Change In Working Capital | $ 247.9 K | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 88.2 M | |
| End Period Cash Flow | $ 127.7 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | $ 2.6 M | |
| Total Operating Expenses | $ 4.1 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ -4.09 M | |
| EBIT | $ -4.09 M | |
| Operating Income | $ -4.09 M | |
| Interest Income | $ 655.5 K | |
| Interest Expense | — | |
| Net Interest Income | $ 655.5 K | |
| Income Before Tax | $ -3.44 M | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | $ -3.44 M | |
| Net Income From Continuing Operations | $ -3.44 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.40 | |
| EPS Actual | $ -0.48 | |
| EPS Difference | $ -0.08 | |
| EPS Surprise | -20.0 % | |
| Forward EPS | $ -0.86 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 144.2 M | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 141.6 M | |
| Total Current Assets | $ 144.1 M | |
| Cash and Short-Term Investments | $ 143.7 M | |
| Cash | $ 127.7 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | $ 2.6 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 2.6 M | |
| Net Debt | — | |
| Total Debt | $ 70.9 K | |
| Total Liabilities | $ 2.6 M | |
| EQUITY | ||
| Total Equity | $ 141.6 M | |
| Retained Earnings | $ -84.31 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 21.25 | |
| Shares Outstanding | 6.663 M | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | $ 476.6 M |
| Enterprise Value | $ 333.0 M | |
| Enterprise Multiple | -81.356 | |
| Enterprise Multiple QoQ | 53.201 % | |
| Enterprise Multiple YoY | 472.455 % | |
| Enterprise Multiple IPRWA | high: 52.77 median: 24.843 mean: 3.676 low: -80.476 MNPR: -81.356 |
|
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.019 | |
| Asset To Liability | 54.632 | |
| Debt To Capital | 0.001 | |
| Debt To Assets | 0.0 | |
| Debt To Assets QoQ | -67.114 % | |
| Debt To Assets YoY | — | |
| Debt To Assets IPRWA | high: 1.045 mean: 0.213 median: 0.074 MNPR: 0.0 low: 0.0 |
|
| Debt To Equity | 0.001 | |
| Debt To Equity QoQ | -67.532 % | |
| Debt To Equity YoY | — | |
| Debt To Equity IPRWA | high: 1.395 mean: 0.193 median: 0.09 MNPR: 0.001 low: -0.869 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 3.367 | |
| Price To Book QoQ | -21.861 % | |
| Price To Book YoY | -41.36 % | |
| Price To Book IPRWA | high: 17.968 mean: 6.972 median: 5.8 MNPR: 3.367 low: -8.555 |
|
| Price To Earnings (P/E) | -149.022 | |
| Price To Earnings QoQ | 35.016 % | |
| Price To Earnings YoY | 584.331 % | |
| Price To Earnings IPRWA | high: 56.753 mean: -3.814 median: -11.943 low: -93.179 MNPR: -149.022 |
|
| PE/G Ratio | -4.012 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | -79.791 | |
| Forward PE/G | -2.148 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | high: 786.053 mean: 191.252 median: 189.366 MNPR: 0 low: -718.796 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 141.6 M | |
| Net Invested Capital | $ 141.6 M | |
| Invested Capital | $ 141.6 M | |
| Net Tangible Assets | $ 141.6 M | |
| Net Working Capital | $ 141.5 M | |
| LIQUIDITY | ||
| Cash Ratio | 55.937 | |
| Current Ratio | 56.098 | |
| Current Ratio QoQ | 65.286 % | |
| Current Ratio YoY | 937.796 % | |
| Current Ratio IPRWA | MNPR: 56.098 high: 25.502 mean: 4.379 median: 3.195 low: 0.02 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -0.017 | |
| Cost Of Debt | 13.223 % | |
| Interest Coverage Ratio | -409.308 | |
| Interest Coverage Ratio QoQ | 26.552 % | |
| Interest Coverage Ratio YoY | 159.894 % | |
| Interest Coverage Ratio IPRWA | high: 815.709 mean: 40.317 median: 4.326 MNPR: -409.308 low: -1538.4 |
|
| Operating Cash Flow Ratio | -0.814 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 167.697 % | |
| Revenue Growth | — | |
| Revenue Growth QoQ | — | |
| Revenue Growth YoY | — | |
| Revenue Growth IPRWA | — | |
| Earnings Growth | 37.143 % | |
| Earnings Growth QoQ | -570.462 % | |
| Earnings Growth YoY | -242.858 % | |
| Earnings Growth IPRWA | high: 162.5 % MNPR: 37.143 % median: -6.452 % mean: -13.185 % low: -198.545 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -2.09 M | |
| Free Cash Flow Yield | -0.439 % | |
| Free Cash Flow Yield QoQ | -8.351 % | |
| Free Cash Flow Yield YoY | -88.386 % | |
| Free Cash Flow Yield IPRWA | high: 30.655 % median: 0.768 % mean: 0.309 % MNPR: -0.439 % low: -58.703 % |
|
| Free Cash Growth | 94.04 % | |
| Free Cash Growth QoQ | -216.133 % | |
| Free Cash Growth YoY | -361.375 % | |
| Free Cash Growth IPRWA | high: 199.867 % MNPR: 94.04 % mean: 27.798 % median: 21.696 % low: -198.468 % |
|
| Free Cash To Net Income | 0.608 | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | 0.608 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | -3.471 % | |
| Return On Assets QoQ | -22.935 % | |
| Return On Assets YoY | -82.37 % | |
| Return On Assets IPRWA | high: 30.5 % median: -0.016 % mean: -2.252 % MNPR: -3.471 % low: -66.968 % |
|
| Return On Capital Employed (ROCE) | -2.89 % | |
| Return On Equity (ROE) | -0.024 | |
| Return On Equity QoQ | -48.34 % | |
| Return On Equity YoY | -90.791 % | |
| Return On Equity IPRWA | high: 0.948 median: -0.002 mean: -0.005 MNPR: -0.024 low: -1.385 |
|
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |